Abstract
Aim To evaluate if suitably designed computed tomography (CT) radiomic signatures are sensitive to tumour transformation, and able to predict disease free survival (DFS) and overall survival (OS) time in patients with pancreatic cancer.
Method Ethical approval by UNSW review board was obtained for this retrospective analysis. This study consisted of 27 patients with pancreatic cancer. Unsupervised principal component analysis was employed to evaluate the sensitivity of radiomic signatures to cancer presence and treatment. Further, optimised radiomic signatures were discovered using swarm intelligence and assessed for their capability to predict DFS and OS based on Kaplan-Meier analysis and receiver-operator characteristics (ROC) curves.
Results We found that appropriate two radiomic signature are sensitive to cancer presence (area under the curve, AUC=0.95) and cancer treatment, respectively. Two other optimized radiomics signatures showed significant correlations with DFS and OS, respectively (p<0.05).
Conclusion The CT radiomics signatures are an independent biomarkers which are modified when cancer is present and can help to estimate DFS and OS in patients. These signatures have the potential to be used to support clinical decision-making in pancreatic cancer treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Australasian Gastro-intestinal Trials Group (AGITG) was the study sponsor and it was coordinated by the National Health and Medical Research Council Clinical Trials Centre (NHMRC-CTC) at the University of Sydney. Specialised Therapeutics Australia supplied the nab-paclitaxel and provided untied financial assistance to conduct the trial.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was centrally approved by the Sydney Local Health District Ethics Review Committee, Royal Prince Alfred Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
